Updated results from the TALAPRO-2 trial “support talazoparib plus enzalutamide as a standard-of-care initial treatment option for patients with mCRPC,” according to Neeraj Agarwal, MD.

Researchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low ...

India's gene therapy for blood cancers shows 73% response rate, offering hope and cost-effective treatment for patients.

An indigenously developed gene therapy for specific blood cancers has shown a 73 per cent response rate among patients in ...

The kindergartners at Platte Center Elementary School are in remission, having battled acute lymphoblastic leukemia (A.L.L.) ...